WindMIL Therapeutics and University♣πγ∞ of California, Irvine Announce Collabor♥σation to Collect Bone Marrow from Pati<≈✔ents with GliomasWEDNESDAY, OCTOBER 16, 2019WindMβ€IL Therapeutics and the University of Californ β$Ωia, Irvine (UCI) today anno♠¶$δunced that the first patients have been identifi↑↑ed in an investigator-sponsored study for the↑ ✔ collection of bone marr®€ow from patients with gliomas. The study w× ill evaluate generating marrow infiltratiσε£γng lymphocytes (MILs™) for the ↑se patients through WindMIL’s proprietary cellulβδ✔ar activation and expansion process. Th↔£e study is being conducted at U<≤÷≤CI.“Patients suffering with gliobα™₩∑lastoma are in great need of new, promising t∏  ≈reatments that might advance the current standard÷‌£ of care,” said Daniela A. Bota, MD, P↕β§₩hD, director of the UCI Hea‍'↓lth Comprehensive Bra↕×¥in Tumor Program, senior as♥↑§φsociate dean for clin↕§ical research, UCI School of Medici¶'©★ne and clinical direct₩↓εor, UCI Sue & Bill Gross Stem Cell Rese£±arch Center. “The University of Californ≈•ia, Irvine is excited to play a key role i∞εn research that may lead↔≠↓  to a clinical trial that enlists the immune∏>&✔ system in novel ways to fight this t ♦errible disease.”Gliomas are the most comm✔‌λ∑on of the malignant brain tumors. → ≠Glioblastoma, the most common glioma, has☆♠☆ a five-year survival of less than 5 percent. Add<¥₽±itional treatment options are ur∏✔gently needed for these p$≈φ₹atients. Adoptive immunotherapy is a possible a±ε€pproach for gliomas and the∏ 'Ω use of MILs, a cell therapy that© ↓© is naturally tumor-sp↕​φ∑ecific, is one such treatment←α☆ option.The bone marrow is a un‍®£©ique niche in the immune system to which an≈¶tigen-experienced memory T cells traf☆×®¥fic and are then maintained. WindMIL∞≈↑≥ has developed a proprietary process to ←§select, activate and ex♣©pand these memory T cells i∞" ≥nto MILs. Because memory T cells in bone ma©↑‌ rrow occur as a result o≠•εσf the immune system’s recognition of tumorε∞ antigens, MILs are s‍φpecifically suited fo≤ r adoptive cellular immunotherapy and are able to©₩☆Ω directly eradicate or fa ∑∑σcilitate eradication of each patient’s unique  ×₹δcancer. WindMIL is currently studying MILs₹‌¥ in multiple myeloma, non-small cell lung ↕↕cancer and squamous cell carci£≠δ noma of the head and neck, and plans to expand∏©δ into other solid tumors.“WindMIL is looking forw♦★∏ard to working with the U♣↕§niversity of California, Irvine on this exciting ×‌‍©project and is optimistic that MILs may offer₹£'  the potential to help pa©✔'σtients with these hard-to-treat disea ↑£↑ses,” said Monil Shah, PharmD, MBA, Chief ×≠Development Officer at WindMIL.informatio©₹n source:pharma¥♠☆ focus AsiaThe original l§>♥ink:https://www.pharmafocu↔屧sasia.com/news/windmil-therapeutics-and-univ©φ£↕ersity-of-california-irvine-announce-collabora≠σ≥tion-to-collect-bone-ma£♥ rrow-from-patients-with-glio ↑≠§mas2019 Asia-pacific pharma IP Leader Summit: ht¥×♣‍tp://en.zenseegroup.com/p/510934♣♦α/will be held in Beijin♦' g  on ↑♦;November 14-15, and will attract↓¥ more than 500 industry experts fr♦♦÷♥om domestic and foreign pharmaceutic↓↔ε al companies, biotechnology companβ→♠Ωies, governments, associations, law firms, in₽¥αtellectual property agents and other companies to<↕ attend.Official registration and consultation≈↕ channels:Contact：AnnPhone: 021-65650305Email&♣：Marketing@zenseegroup.comht±¶tp://en.zenseegroup.com/p/510934/